Acromegaly Treatment: 24 hours • 1 dose
The PATHFNDR study is recruiting patients to participate in clinical research for once-daily paltusotine for the treatment of acromegaly. Paltusotine could be the only once-daily, oral therapy that gives patients who are looking for an alternative to injections or twice-daily orals another treatment option.
As a study participant, you could play an important role in making acromegaly treatment easier for yourself and many others living with this rare disease.
About the Study
The purpose of the PATHFNDR study is to see if Crinetics Pharmaceuticals’ investigational medication, paltusotine, is safe and effective in patients with acromegaly.
Who Can Participate?
You may be able to participate in this study if you:
- Are 18 years of age or older
- Have medically stable, confirmed-active acromegaly